Loading company…
Maat Pharma develops microbiome-based therapies intended to improve cancer treatment outcomes, based in Lyon, France.
Founded in 2013 and headquartered in Lyon, France, Maat Pharma develops microbiome-based treatments for cancer patients, including Xervyteg, MaaT033, MaaT034 and MaaT03X, marketed to healthcare institutions and specialized clinics in Europe and North America. CEO and founder Herve Affagard leads the company, which has completed 8 deals. Its most recent round, on January 15, 2021, raised EUR 7.35 mn in Series B funding led by Bpifrance, alongside Celeste Management and Skyviews Life Science.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in